About this trial
The aim of this study is to evaluate the impact of sustained thrombectomy with INDIGO ASPIRATION SYSTEM using CAT RX versus no thrombectomy during primary percutaneous coronary intervention (PPCI) on microvascular obstruction and infarct size, as measured by cardiovascular magnetic resonance (CMR) between 3 and 5 days post PPCI, in patients with anterior STEMI
Eligibility criteria
Qualifiers
Age >18 and <75 years old
Acute anterior STEMI with ≥2 mm in two (2) or more contiguous anterior leads or ≥4 mm total ST-segment deviation sum in the anterior leads V1-V4 AND anterior wall motion abnormality noted on a diagnostic quality left ventriculogram or echocardiogram
Culprit lesion proximal or mid LAD at coronary angiography
TIMI thrombus grading > 3 or TIMI flow 0 after guidewire crossing the lesion.
Disqualifiers
Unable to give Informed consent.
Life expectancy < 1 year.
Contraindication to PCI
STEMI due to stent thrombosis
Trial design
Treatments tested in this trial
- THROMBOASPIRATION WITH INDIGO SYSTEM
Treatment groups
Sponsors and collaborators
Ceric Sàrl
Lead sponsor
European Cardiovascular Research Center
Collaborator